BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/24/2021 2:07:00 AM | Browse: 677 | Download: 1469
 |
Received |
|
2021-01-04 17:53 |
|
Peer-Review Started |
|
2021-01-04 17:54 |
|
First Decision by Editorial Office Director |
|
2021-04-25 18:01 |
|
Return for Revision |
|
2021-04-25 18:01 |
|
Revised |
|
2021-04-27 14:58 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-07-06 10:04 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-07-06 10:31 |
|
Articles in Press |
|
2021-07-06 10:31 |
|
Edit the Manuscript by Language Editor |
|
2021-07-19 02:01 |
|
Typeset the Manuscript |
|
2021-08-16 03:41 |
|
Publish the Manuscript Online |
|
2021-08-24 02:07 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xin Wang, Yan-Fen Shi, Jiang-Hui Duan, Chao Wang and Huang-Ying Tan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Huang-Ying Tan, MD, PhD, Chief Physician, Department of Integrative Oncology, China-Japan Friendship Hospital, No. 2 Yinghuadong Street, Beijing 100029, China. tanhuangying@263.net |
| Key Words |
Neuroendocrine carcinoma; Breast; S-1; Temozolomide; Case report |
| Core Tip |
Neuroendocrine carcinoma of the breast (NECB) are highly malignant tumours. There is no standard treatment protocol for NECB due to its rarity. we treated this patient with the S-1 combined with temozolomide (STEM) regimen as second-line treatment due to disease progression. The effect of the STEM regimen on the patient was good, and she achieved a progression-free survival of 23 mo. During the chemotherapy period, the patient achieved a partial response and suffered only grade-1 adverse reactions. This report can serve as a reference for clinical practice. |
| Publish Date |
2021-08-24 02:07 |
| Citation |
Wang X, Shi YF, Duan JH, Wang C, Tan HY. S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report. World J Clin Cases 2021; 9(24): 7146-7153 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i24/7146.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i24.7146 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
